Oppenheimer Sees No Read Through to Other Ionis Pharmaceuticals (IONS) Programs From Tominersen Discontinuation
- Nasdaq closes up on tech stocks strength, as hawkish Fed limits S&P
- Dollar surges to two-month high on Fed rate-hike projection
- BofA Fund Manager Survey: 72% Says Inflation 'Transitory', 63% Expect Fed to Signal Taper Aug/Sept, 'Long Commodities' Now the Most Crowded Trade
- Oil falls from multi-year highs on firmer dollar, hike in UK COVID cases
- People Are Spending More Time Outdoors, Which Will Hurt Netflix (NFLX) This Quarter - KeyBanc
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Oppenheimer analyst Kevin DeGeeter reiterated an Outperform rating and $63.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) after Roche announced discontinuation of Phase III GENERATION HD1 study of tominersen for HD. IONS management was emphatic there is no direct read through to other programs. Given absence of any notable confirmed AEs for tominersen and paucity of target engagement / phenotype data for HD, expansive interpretation of the Phase III discontinuation is not likely.
The analyst stated "We do not see read through to ASO backbone or other IONS neurodegenerative disease studies." He went on to state "Failure is in line with our outlook but timing (study stopped 12-plus months prior to expected follow up on primary endpoint) was a surprise. While we see additional risk with Tofersen Phase III readout for SOD-1 ALS in 2H21, we view current valuation as offering an attractive entry point for investors with 9-plus month outlook."
Shares of Ionis Pharmaceuticals closed at $44.76 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: RBC Capital Starts FS KKR Group (FSK) at Sector Perform
- UPDATE: Janney Starts Sachem Capital Corp. (SACH) at Buy
- Cafe de Coral Holdings Ltd (341:HK) PT Lowered to HK$19.30 at Nomura/Instinet
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!